Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning™ antibody therapeutics that enhance the body’s antitumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced today that PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on macrophages 1), was well-tolerated with signals...
